Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$29.83 USD

29.83
4,829,456

+0.57 (1.95%)

Updated May 3, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 22% (196 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sarepta (SRPT) Q2 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

Sarepta's (SRPT) second-quarter 2023 earnings beat estimates. Though total revenues register strong year-over-year growth during the quarter, the same misses the mark.

Blueprint (BPMC) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Blueprint (BPMC) reports better-than-expected second-quarter 2023 results, driven by increased Ayvakit sales, following FDA approval in a new indication.

Roche (RHHBY) 1H Revenues, Earnings Down on Lower COVID-19 Test Sales

by Zacks Equity Research

Roche's (RHHBY) performance in the first half of 2023 was ordinary as COVID-19-test sales continue to decline and dent the top line.

Biogen (BIIB) Beats on Q2 Earnings & Sales, Announces Job Cuts

by Zacks Equity Research

Biogen (BIIB) beats second-quarter estimates for earnings and sales. It maintains 2023 guidance. Stock up in pre-market.

Will AbbVie's (ABBV) New Drugs Make Up for Low Humira Sales?

by Zacks Equity Research

In its Q2 earnings results, AbbVie's (ABBV) Skyrizi and Rinvoq sales are expected to have made up for the declining Humira sales following the loss of U.S. exclusivity.

Alnylam (ALNY) to Co-Develop Hypertension Drug With Roche

by Zacks Equity Research

Alnylam (ALNY) collaborates with Roche to co-develop and co-commercialize RNAi-based therapeutic, zilebesiran, for the treatment of hypertension in patients with high cardiovascular risk.

Roche (RHHBY) SMA Drug Gets Positive CHMP Opinion for Expanded Use

by Zacks Equity Research

Roche's (RHHBY) Evrysdi gets a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for extended use in infants under two months with spinal muscular atrophy.

AbbVie (ABBV) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

AbbVie's (ABBV) Q2 performance will likely reflect Skyrizi and Rinvoq sales trying to make up for the declining Humira sales following the loss of U.S. exclusivity.

Biogen (BIIB) to Report Q2 Earnings: Here's What to Expect

by Zacks Equity Research

Biogen's sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have improved.

The Zacks Analyst Blog Highlights Roche, Fomento Economico Mexicano, Advanced Micro Devices, Union Pacific and Mondelez International

by Zacks Equity Research

Roche, Fomento Economico Mexicano, Advanced Micro Devices, Union Pacific and Mondelez International are included in this Analyst Blog.

Sheraz Mian headshot

Q2 Earnings Scorecard and Analyst Reports for Roche, AMD & Others

by Sheraz Mian

Today's Research Daily features a real-time update on the Q2 earnings season and fresh analyst reports on Roche (RHHBY), AMD (AMD) and 16 other companies.

Lilly's (LLY) Donanemab Slows Alzheimer's Disease Progression

by Zacks Equity Research

Data from a phase III study shows that treatment with Eli Lilly's (LLY) donanemab slowed cognitive and functional decline by 60% in study participants at the earliest stage of Alzheimer's disease.

Roivant (ROIV) Up on Reports of Colitis Drug Sale to Roche

by Zacks Equity Research

Roivant's (ROIV) RVT-3101, a once-monthly subcutaneously administered anti-TL1A antibody, is being developed for ulcerative colitis and Crohn's disease

Halozyme (HALO) Rises 5% as Ocrevus SC Meets Goals in MS Study

by Zacks Equity Research

Halozyme (HALO) rises 5% after Roche's late-stage multiple sclerosis study of subcutaneous co-formulation of Ocrevus developed with its Enhanze technology meets goals.

ADC Therapeutics (ADCT) Dips on Halting Zynlonta Study

by Zacks Equity Research

ADC Therapeutics (ADCT) pauses patient enrollment in a mid-stage study evaluating Zynlonta in combination with rituximab, for patients with previously untreated diffuse large B-cell lymphoma who are unfit or frail.

Roche (RHHBY) Blood Cancer Drug Columvi Wins EC Approval

by Zacks Equity Research

Roche's (RHHBY) blood cancer portfolio gets a boost with the EC's approval of Columvi (glofitamab-gxbm) for treating patients with R/R DLBCL.

Biogen (BIIB) Stock Down Despite FDA Nod to Alzheimer's Drug

by Zacks Equity Research

Biogen (BIIB) stock falls despite Leqembi getting the traditional nod for the treatment of Alzheimer's Disease.

Biogen (BIIB), Eisai Get Full FDA Nod for Leqembi in Alzheimer's

by Zacks Equity Research

Following the full approval, Biogen (BIIB)/Eisai's Leqembi is the first approved treatment to slow progression of Alzheimer's disease. This also paves the way for a broader Medicare coverage.

Sarepta (SRPT) Sells Priority Review Voucher for $102M

by Zacks Equity Research

Sarepta (SRPT) sells its priority review voucher that was awarded following the FDA's approval to Elevidys gene therapy for treating DMD. The company will invest these proceeds into R&D.

Regeneron (REGN) Loses 13% in Three Months: What Lies Ahead?

by Zacks Equity Research

Regeneron (REGN) declines 13% in the last three months due to regulatory setback for 8 mg dose strength of aflibercept and competition for lead drug.

Roche (RHHBY) Announces Positive Long-Term Data on SMA Drug

by Zacks Equity Research

Roche's (RHHBY) SMA drug Evrysdi maintains its efficacy and safety profile in children with type 1 SMA after four years of treatment.

FDA Accepts Pfizer's (PFE) Hemophilia B Gene Therapy Filing

by Zacks Equity Research

A final decision on Pfizer's (PFE) BLA filing, seeking approval for hemophilia B gene therapy, treatment is expected by second-quarter 2024.

Sarepta (SRPT) Gets FDA's Accelerated Nod for DMD Gene Therapy

by Zacks Equity Research

Following FDA???s approval, Sarepta's (SRPT) Elevidys becomes the first gene therapy for treating DMD.

Roche (RHHBY) Gets FDA Approval for Blood Cancer Drug Columvi

by Zacks Equity Research

Roche's (RHHBY) blood cancer portfolio gets a boost with the approval of Columvi (glofitamab-gxbm) for treating patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Novartis (NVS) to Buy Chinook for $3.5B to Strengthen Pipeline

by Zacks Equity Research

Novartis (NVS) is looking to strengthen its renal pipeline with the acquisition of Chinook Therapeutics for $3.5 billion, which adds two late-stage medicines in development for rare, severe chronic kidney diseases.